From:  Survodutide for MASH: disentangling weight-dependent from weight-independent liver effects

 Key clinical trials of lifestyle and pharmacological interventions for NASH/MASH: histological and fibrosis outcomes.

Author/Year/RefMethodsKey findingsConclusion
Vilar-Gomez et al., 2015 [14]Prospective, 52-week lifestyle-intervention cohort of 293 adults with biopsy-proven NASH; 261 had paired liver biopsies. Participants received dietary and physical-activity counselling, and histological change was related to achieved weight loss.Overall, 25% achieved NASH resolution, 47% had a reduction in NAFLD Activity Score, and 19% had fibrosis regression. Among patients losing ≥ 10% of body weight, all had a reduction in activity score, 90% achieved NASH resolution, and 45% had fibrosis regression.Lifestyle-induced weight loss was associated with graded histological benefit; 7%–10% reduction in body weight was associated with meaningful histological improvement, whereas weight loss ≥ 10% may induce higher rates of NASH resolution and fibrosis regression.
Newsome et al., 2021 [15]Double-blind, phase 2 trial of 320 adults with biopsy-confirmed NASH and F1–F3 fibrosis, randomly assigned to once-daily s.c. semaglutide 0.1 mg, 0.2 mg, or 0.4 mg, or placebo, for 72 weeks. Primary histological analyses focused on participants with F2–F3 fibrosis.NASH resolution without fibrosis worsening occurred in 59% with semaglutide 0.4 mg versus 17% with placebo. Fibrosis improvement occurred in 43% versus 33%, a non-significant difference. Mean weight loss was 13% versus 1%, with gastrointestinal adverse events more frequent on semaglutide.Semaglutide substantially increased NASH resolution but did not significantly improve fibrosis, indicating a strong effect on disease activity without established antifibrotic efficacy in this trial.
Harrison et al., 2024 [16]Ongoing, double-blind, phase 3 trial in 966 adults with biopsy-confirmed NASH and F1B–F3 fibrosis, randomly assigned 1:1:1 to oral resmetirom 80 mg, resmetirom 100 mg, or placebo once daily. Dual primary histological endpoints were assessed at 52 weeks.NASH resolution without fibrosis worsening occurred in 25.9% and 29.9% with resmetirom 80 mg and 100 mg, respectively, versus 9.7% with placebo. Fibrosis improvement by at least one stage without worsening of activity score occurred in 24.2% and 25.9%, respectively, vs. 14.2% with placebo; LDL cholesterol also fell significantly.Both resmetirom doses improved steatohepatitis resolution and fibrosis compared with placebo, supporting liver-directed thyroid hormone receptor-β agonism as an effective disease-modifying strategy.
Sanyal et al., 2024 [17]In this 48-week phase 2 trial, adults with biopsy-proven MASH and fibrosis stage F1–F3 were randomly assigned in a 1:1:1:1 ratio to receive once-weekly s.c. survodutide at 2.4, 4.8, or 6.0 mg, or placebo. The trial included a 24-week rapid dose-escalation phase followed by a 24-week maintenance phase. The primary endpoint was histologic improvement in MASH without worsening of fibrosis. Secondary endpoints included ≥ 30% reduction in LFC and biopsy-proven fibrosis improvement of ≥ 1 stage.Among 293 randomized participants who received ≥ 1 dose of study drug, MASH improvement without fibrosis worsening occurred in 47%, 62%, and 43% of those receiving survodutide 2.4, 4.8, and 6.0 mg, respectively, vs. 14% with placebo (P < 0.001 for the quadratic dose–response model). LFC fell by ≥ 30% in 63%, 67%, 57% and 14% of participants, respectively, and fibrosis improved by ≥ 1 stage in 34%, 36%, 34% and 22%. Nausea, diarrhea, and vomiting were more common with survodutide than placebo (66% vs. 23%, 49% vs. 23%, and 41% vs. 4%, respectively), whereas serious adverse events were similar between groups.Survodutide improved MASH without worsening fibrosis more effectively than placebo, supporting further evaluation in phase 3 trials.
Sanyal et al., 2025 [18]Ongoing multicenter, randomized, double-blind, placebo-controlled phase 3 trial of 1,197 adults with biopsy-defined MASH and F2–F3 fibrosis, assigned 2:1 to once-weekly s.c. semaglutide 2.4 mg or placebo for 240 weeks. The planned week-72 interim analysis included the first 800 participants.MASH resolution without fibrosis worsening occurred in 62.9% with semaglutide versus 34.3% with placebo. Fibrosis improvement without worsening of MASH occurred in 36.8% versus 22.4%, and combined MASH resolution and fibrosis improvement in 32.7% versus 16.1%. Mean body-weight change was −10.5% versus −2.0%.Once-weekly semaglutide 2.4 mg improved both steatohepatitis and fibrosis outcomes in patients with MASH and moderate or advanced fibrosis, although longer-term follow-up remains ongoing.

LDL: low-density lipoprotein; LFC: liver fat content; MASH: metabolic dysfunction-associated steatohepatitis; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; s.c.: subcutaneous.